Skip to main content

Table 2 Hazard ratios and corresponding 95% confidence intervals for the association between circulating OPG concentration at blood collection and survival outcomes, stratified by ERPR status

From: Postdiagnosis circulating osteoprotegerin and TRAIL concentrations and survival and recurrence after a breast cancer diagnosis: results from the MARIE patient cohort

  

OPG, all cases

 

ER-PR-

 

ER+ PR− or ER-PR + 

 

ER + PR + 

  

n/events

HRa

(95% CI)

p

 

n/events

HRb

(95% CI)

p

 

n/events

HRb

(95% CI)

p

 

n/events

HRb

(95% CI)

p

Phetc

All-cause mortality

Quartiles

1

613/108

 

 ref.

  

68/14

 

 ref.

  

88/15

 

 ref.

  

396/68

 

 ref.

  
 

2

614/102

0.85

(0.65–1.12)

  

79/16

0.94

(0.45–1.99)

  

103/20

1.08

(0.54–2.13)

  

370/56

0.84

(0.59–1.20)

 

0.44

 

3

615/122

0.97

(0.75–1.27)

  

69/22

1.40

(0.70–2.82)

  

88/16

0.89

(0.43–1.85)

  

392/72

0.96

(0.68–1.35)

  
 

4

614/152

1.21

(0.93–1.56)

  

93/34

1.75

(0.90–3.40)

  

88/23

1.58

(0.81–3.06)

  

377/85

1.09

(0.78–1.52)

  

Continuousd

2456/484

1.24

(1.03–1.49)

0.03

 

309/86

1.93

(1.20–3.10)

0.01

 

367/74

1.70

(1.03–2.81)

0.04

 

1535/281

1.06

(0.83–1.35)

0.64

0.09

Breast cancer-specific mortality

Quartiles

1

613/72

 

 ref.

  

68/10

 

 ref.

  

88/10

 

 ref.

  

396/44

 

 ref.

  
 

2

614/55

0.71

(0.50–1.02)

  

79/12

1.11

(0.46–2.69)

  

103/14

1.20

(0.52–2.76)

  

370/24

0.56

(0.34–0.92)

 

0.48

 

3

615/71

0.86

(0.62–1.21)

  

69/15

1.40

(0.60–3.27)

  

88/11

1.04

(0.43–2.53)

  

392/35

0.75

(0.48–1.18)

  
 

4

614/78

0.97

(0.70–1.36)

  

93/18

1.33

(0.58–3.09)

  

88/15

1.66

(0.73–3.77)

  

377/40

0.80

(0.51–1.26)

  

Continuousd

2456/276

1.08

(0.84–1.39)

0.53

 

309/55

1.37

(0.75–2.48)

0.30

 

367/50

1.78

(0.96–3.30)

0.07

 

1535/143

0.92

(0.66–1.29)

0.63

0.09

Recurrence-free survivale

Quartiles

1

558/117

 

 ref.

  

62/13

 

 ref.

  

83/18

 

 ref.

  

376/83

 

 ref.

  
 

2

566/116

0.92

(0.71–1.20)

  

75/20

1.32

(0.64–2.73)

  

99/20

0.86

(0.45–1.65)

  

353/71

0.86

(0.63–1.19)

 

0.05

 

3

555/129

1.09

(0.84–1.40)

  

63/22

1.93

(0.94–3.97)

  

81/17

0.89

(0.45–1.76)

  

371/86

0.99

(0.73–1.34)

  
 

4

560/145

1.13

(0.88–1.46)

  

88/37

2.35

(1.20–4.58)

  

84/23

1.31

(0.70–2.45)

  

352/83

0.93

(0.67–1.27)

  

Continuousd

2239/507

1.16

(0.97–1.39)

0.11

 

288/92

2.18

(1.39–3.40)

 < 0.001

 

347/78

1.50

(0.92–2.45)

0.11

 

1452/323

0.97

(0.77–1.21)

0.77

0.01

  1. ERPR status was not available for 91 women who had neoadjuvant chemotherapy and 154 who were diagnosed tumor in situ or stage 0. ERPR-discordant includes ER+PR-, ER-PR+, ER+ or PR+ and data on other receptor unknown, or women treated with tamoxifen or aromatase inhibitor
  2. aAdjusted for age, nodal status, tumor size, and grade/ strata for center, ERPR status
  3. bAdjusted for age, nodal status, tumor size, and grade/ strata for center
  4. cHeterogeneity of estimates across ERPR status
  5. dLog2 transformed
  6. ePatients without information on recurrence or with a tumor stages 3b, and 3c were excluded